CLPT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ClearPoint Neuro Inc (CLPT) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company demonstrates strong revenue growth and potential upside in the gene therapy market, the stock's current technical indicators, lack of positive trading signals, and mixed analyst sentiment suggest it is better to hold off on investment until more favorable conditions arise.
The stock's technical indicators show bearish moving averages (SMA_200 > SMA_20 > SMA_5), suggesting a downward trend. The RSI at 36.628 is neutral, and the MACD histogram is above 0 but positively contracting. The stock is trading near its support level of 8.716, with resistance at 9.169. Overall, the technical outlook is weak.
The company reported strong Q4 revenue growth of 34% YoY and has 13 partners under FDA expedited review, which could lead to significant future upside. Gross margin also increased slightly to 61.52%.
The stock has faced recent setbacks, including the FDA's rejection of uniQure's AMT-130 BLA, which has negatively impacted sentiment. Additionally, the company lowered its 2026 guidance due to the removal of certain partner revenue and a reset of IRRAS's European distribution.
In Q4 2025, revenue increased by 33.96% YoY to $10.41M, and net income improved by 44.56% YoY to -$7.79M. EPS also improved by 35% YoY to -0.27. While these figures show growth, the company remains unprofitable.
Analysts maintain a Buy rating with a price target of $20, up from $18. However, the stock has faced mixed sentiment due to near-term uncertainties and lowered guidance. The base business valuation is estimated at $12/share, with expected 25% organic revenue growth in 2026.
